A Phase Ib Trial of Neoadjuvant Durvalumab (MEDI4736) +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2017
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 05 Jan 2017 Status changed from not yet recruiting to recruiting.
- 05 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.